High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

Conditions:   Atherosclerotic Cardiovascular Disease;   Symptomatic Atherosclerosis;   Type2 Diabetes;   Familial Hypercholesterolemia
Interventions:   Drug: Inclisiran;   Drug: Evolocumab
Sponsor:   The Medicines Company
Not yet recruiting - verified February 2017

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Condition:   Hypercholesterolemia
Interventions:   Drug: Bempedoic acid 180mg;   Drug: Ezetimibe 10mg;   Drug: Atorvastatin 20mg;   Other: Placebo
Sponsor:   Esperion Therapeutics
Recruiting - verified February 2017

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Condition:   Hypercholesterolemia
Interventions:   Drug: Praluent (Alirocumab);   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: statins;   Drug: ezetimibe;   Drug: cholestyramine;   Drug: fenofibrate;   Drug: omega-3 fatty acids;   Drug: nicotinic acid
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2017

Study to Evaluate the Safety of Repatha® in Pregnancy

Conditions:   Hypercholesterolaemia;   Pregnancy
Intervention:  
Sponsor:   Amgen
Recruiting - verified February 2017

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting - verified February 2017

Graves' Orbitopathy and Hypercholesterolemia

Conditions:   Graves' Ophthalmopathy;   Hypercholesterolemia
Intervention:   Other: No intervention
Sponsor:   University of Pisa
Recruiting - verified February 2017

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2017

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:   Biological: AAV directed hLDLR gene therapy
Sponsor:   University of Pennsylvania
Recruiting - verified January 2017

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Conditions:   Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Completed - verified February 2017

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Conditions:   Diabetes Mellitus;   Hypertension;   Coronary Artery Disease;   Atrial Fibrillation;   Stroke
Interventions:   Other: PHCVRS Intervention;   Other: Personal Health Record
Sponsor:   Barry L. Carter
Active, not recruiting - verified February 2017

Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia

Condition:   Homozygous Familial Hypercholesterolemia
Interventions:   Genetic: Gene analysis;   Other: Historical data of lipid-lowering drug administration;   Other: Historical data of plasma lipids, xanthoma changes
Sponsor:   Central South University
Completed - verified February 2017

Study of a Holistic Health Program for United Methodist Clergy

Conditions:   Obesity;   Depression;   Diabetes;   Hypertension;   Hypercholesterolemia
Intervention:   Behavioral: Holistic health
Sponsors:   Duke Clergy Health Initiative;   The Duke Endowment
Completed - verified February 2017

Functional and Cognitive Impairment in Advanced Kidney Disease

Condition:   Kidney Insufficiency, Chronic
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2017

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Conditions:   Hypercholesterolemia;   Hyperlipidemia
Interventions:   Drug: niacin (+) laropiprant;   Drug: niacin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Conditions:   Hypercholesteremia;   Hyperlipidemia
Interventions:   Drug: MK-0524A;   Drug: ER Niacin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

Conditions:   HYPERTENSION;   HYPERCHOLESTEROLEMIA
Intervention:   Drug: valsartan + simvastatin
Sponsor:   Novartis
Completed - verified February 2017

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Conditions:   Mixed Dyslipidemia;   Hypercholesterolemia
Intervention:   Drug: Fluvastatin
Sponsor:   Novartis
Completed - verified February 2017